Neurobiological Technologies (Neurobiological Technologies) ROCE % : 78.19% (As of Sep. 2009)

View and export this data going back to 1994. Start your Free Trial

What is Neurobiological Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Neurobiological Technologies's annualized ROCE % for the quarter that ended in Sep. 2009 was 78.19%.

Neurobiological Technologies ROCE % Historical Data

The historical data trend for Neurobiological Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurobiological Technologies ROCE % Chart

Neurobiological Technologies Annual Data

Trend

Jun00

Jun01

Jun02

Jun03

Jun04

Jun05

Jun06

Jun07

Jun08

Jun09

ROCE %

Get a 7-Day Free Trial

-94.13

-174.04

-325.39

-108.27

10.83

Neurobiological Technologies Quarterly Data
	Dec04	Mar05	Jun05	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09
ROCE %	Get a 7-Day Free Trial															-40.60	-134.69	-6.26	289.01	78.19

Neurobiological Technologies ROCE % Calculation

Neurobiological Technologies's annualized ROCE % for the fiscal year that ended in Jun. 2009 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2009 )		(A: Jun. 2008 )		(A: Jun. 2009 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2009 )		(A: Jun. 2008 )		(A: Jun. 2009 )
	=	3.123	/	( ( (43.187 - 9.042)	+	(24.66 - 1.115) )	/ 2 )
	=	3.123	/	( (34.145	+	23.545)	/ 2 )
	=	3.123	/	28.845
	=	10.83 %

Neurobiological Technologies's ROCE % of for the quarter that ended in Sep. 2009 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2009 )		(Q: Jun. 2009 )		(Q: Sep. 2009 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2009 )		(Q: Jun. 2009 )		(Q: Sep. 2009 )
	=	20.592	/	( ( (24.66 - 1.115)	+	(29.782 - 0.655) )	/ 2 )
	=	20.592	/	( ( 23.545	+	29.127 )	/ 2 )
	=	20.592	/	26.336
	=	78.19 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2009) EBIT data.

Neurobiological Technologies (OTCPK:NTII) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Neurobiological Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Neurobiological Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurobiological Technologies (Neurobiological Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurobiological Technologies Inc (OTCPK:NTII) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2010 Crow Canyon Place, Suite 100, San Ramon, CA, USA, 94583

Website

http://www.ntii.com

Neurobiological Technologies Inc is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.

Executives

Ariel Warszawski	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Ryan Heslop	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Management Co Gp, Llc	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Fvp Gp, Llc	10 percent owner	C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Value Partners, Lp	10 percent owner	426 PINEVILLE ROAD, UNIT 1, NEWTOWN PA 18940
Fvp Master Fund Lp	10 percent owner	FVP GP LLC, 551 FIFTH AVENUE, 36TH FLOOR, New York NY 10176
John B Stuppin	director
Abraham E Cohen	director	500 SEVENTH AVE 10TH FL, C/O AXONYX INC, NEW YORK NY 10018
Abraham D Sofaer	director	HOOVER INSTITUTION, STANFORD UNIVERSITY, STANFORD CA 94305-6010
Biotechnology Value Fund L P	other: Direct Beneficial Owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: Direct Beneficial Owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Investments Llc	other: Direct Beneficial Owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Neurobiological Technologies (Neurobiological Technologies) Headlines

From GuruFocus

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus • 02-12-2009

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus • 05-09-2009

Neurobiological Technologies Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-12-2010